Resivant Medical Receives FDA Clearance for Two Novel High-Viscosity Tissue Adhesive Products Cutiva™ Topical Skin Adhesive and Cutiva™ PLUS Skin Closure System

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 08/23/2024.
  • Additional Information
    • Alternate Title:
      RESIVANT-fda-approval
    • Subject Terms:
    • Abstract:
      AKRON, Ohio, Aug. 23, 2024 /PRNewswire/ -- Resivant Medical announced today it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its first two products, Cutiva™ Topical Skin Adhesive, and Cutiva PLUS™ Skin Closure System, which combines an adhesive mesh patch with high-viscosity Cutiva™ liquid adhesive. This achievement represents a significant advancement in medical tissue adhesive and wound closure technology and marks the first major adhesive advancement in over 25 years. [ABSTRACT FROM PUBLISHER]